MeiraGTx Holdings PLC Xerostomia Clinical Program Update Call Transcript
Thank you for joining us today as we give an update of our AAV-hAQP1 program for the treatment of radiation-induced xerostomia. Before we begin, please note that we'll be making forward-looking statements as part of this presentation, which are subject to certain risks and uncertainties that may cause actual results, performance or achievements to materially differ from those forecast. Certain of these risks are described on Slide 2 of today's presentation and in our most recent filings with the SEC.
I'm Zandy Forbes, the President and CEO of Meira. I'm joined by Dr. Robert Zeldin, our Chief Medical Officer; and by Dr. Michael Brennan, Chairman of the Department of Oral Medicine and Director of Sjogren's Syndrome and Salivary Disorders Center at Carolinas Medical Center in Charlotte, North Carolina.
I will turn it over to Robert to first provide an overview of radiation-induced xerostomia with some insight into the unmet need of this patient population.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |